Post-Conference Perspectives
February 11, 2020 –
Before concluding his discussion on the management of B-cell malignancies, an expert shares insight on the ongoing challenges in this space.
February 11, 2020 –
Specific considerations for the future roles of payers and care providers as the B-cell malignancy treatment landscape evolves.
February 04, 2020 –
Due to cost of novel therapeutic strategies, an expert shares insight on how these agents could be integrated into treatment pathways.
February 04, 2020 –
Homing in on specific Bruton tyrosine kinase inhibitors used to treat B-cell malignancies, an expert considers selecting one agent over another.
February 03, 2020 –
The panelist shares his thoughts on unmet needs and the future of therapy in the management of multiple myeloma.
February 03, 2020 –
An expert provides an understanding of de-escalation or maintenance therapy and shares treatment plans for relapsed/refractory multiple myeloma.
January 28, 2020 –
A review of the rationale behind Bruton tyrosine kinase inhibitors and their role in managing B-cell malignancies.
January 28, 2020 –
In-depth considerations for the coverage, access, and cost of novel therapeutic agents used to treat B-cell malignancies.
January 21, 2020 –
Expert insight on National Comprehensive Cancer Network guidelines with deference to chronic lymphocytic leukemia and mantle cell lymphoma.
January 21, 2020 –
A comprehensive review of the individual diseases that constitute B-cell malignancies.
